Sertraline Treatment for Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
J Clin Psychiatry 2006;67(6):874-881
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: This study assessed the
efficacy and safety of sertraline in the treatment of
generalized anxiety disorder (GAD).
Method: The study was conducted from
April 2000 to May 2002. Outpatients with DSM-IV GAD (N = 326) who satisfied
inclusion/exclusion criteria and completed a 1-week screening
phase were randomly assigned to 10-week
double-blind treatment with flexible dosing of sertraline
(50-200 mg/day) or placebo. The primary efficacy measure was change from baseline in
Hamilton Rating Scale for Anxiety (HAM-A) total
score. Response was defined as a 50% or greater decrease in HAM-A total score at endpoint.
Results: Sertraline produced a
statistically significant reduction in anxiety symptoms,
as measured by HAM-A total change scores (p = .032), HAM-A psychic anxiety
subscale (p = .011), and Hospital Anxiety and
Depression Scale-anxiety subscale (p = .001). Response
rates were significantly higher (p = .05) for the sertraline group (59.2%) compared to the placebo group (48.2%). Sertraline was well tolerated,
with only sexual side effects reported
significantly more often by subjects receiving sertraline
than those receiving placebo.
Conclusion: Despite the relatively small
between-group differences, study findings suggest
a role for sertraline in the acute treatment of GAD.